Physician profile
Anu R Lamba
NPI 1962601328
$4,656.17
in general payments reported to CMS, 2019-2025
26 companies · $738 in 2025
The $738 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $898 · 2020: $187 · 2021: $380 · 2022: $892 · 2023: $576 · 2024: $984 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,298.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,899.68 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $526.70 | 2019-2025 | Stelara, Remicade, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.74 | 2019-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $318.30 | 2019-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $164.21 | 2019-2025 | Sucraid |
| Lilly USA, LLC | $149.63 | 2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $147.51 | 2020-2024 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $142.13 | 2019-2021 | |
| Ethicon US, LLC | $112.91 | 2019 | |
| Pfizer INC. | $96.34 | 2021-2022 | |
| Daiichi Sankyo INC. | $87.72 | 2020-2023 | Injectafer |
| Celgene Corporation | $86.26 | 2022-2023 | Zeposia |
| Enterra Medical, INC. | $67.08 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $66.71 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $58.71 | 2019-2025 | Ocaliva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $58.40 | 2019 | |
| Genzyme Corporation | $55.31 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $47.67 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $44.97 | 2019-2021 | |
| Organon LLC | $38.19 | 2021-2022 | |
| Redhill Biopharma INC. | $37.60 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $35.20 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $23.64 | 2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $14.23 | 2019 | |
| Novo Nordisk INC | $11.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Lamba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.